Carl Zeiss Meditec : Conference Call Presentation 12M 2021/22

Carl Zeiss Meditec Group

Annual Results FY 2021/22

Dr. Markus Weber, President and CEO		December 09, 2022
Justus Felix Wehmer, CFO

Agenda

01 12M 2021/22 at a Glance

02 Financial Performance

03 Focus Topics

04 Outlook

ZEISS

Page 2

Continued growth in revenue and earnings in FY 2021/22

Revenue

12M 2021/22

12M 2020/21

€ 1,902.8 million

+15.5%

1,646.8

• 12M revenue grew by 15.5% (FX-adj. 13.3%) - continued positive development of recurring revenue and device business
• Growth supported by all regions, led again by APAC
• Strong demand partially constrained by supply chain - order intake at € 2,251 m, +30% yoy

EBIT

12M 2021/22

12M 2020/21

€ 396.9 million

+6.2%

373.6

• EBIT margin at 20.9% (PY 22.7%), adj. EBIT margin at 21.4% (PY 23.0%)
• Lower margin mainly due to planned high investment in R&D as well as S&M arising from new product launches and return to physical tradeshows
• Gross Margin improved from 58.7% in PY to 59.3%, as favorable product mix with high recurring revenue and positive FX environment mitigated inflation in material and payroll cost

12M 2021/22

12M 2020/21

EPS

€ 3.29		Earnings per share above PY, proposed dividend of € 1.10 per share
+24.4%		Continued hedging loss offset by positive other financial results mainly due to revaluation of
2.64		purchase price liabilities, also leading to lower tax rate

ZEISS

Page 3

Agenda

01 12M 2021/22 at a Glance

02 Financial Performance

03 Focus Topics

04 Outlook

ZEISS

Page 4

Ophthalmic Devices

Strong revenue trend with continuously rising share of recurring business

			Revenue
12M 2021/22		€ 1,469.3 million	 Major growth contribution by recurring revenues, strong equipment order intake
12M 2020/21	+17.0%	 FX-adj. revenue increased by 15.0%
1,255.7

EBIT margin

12M 2021/22

12M 2020/21

20.7%

-2.2 pps

22.9%

• EBIT margin decline of -2.2 pps due to:

• Higher sales & marketing expenses due partly to new product launches and return to physical trade shows and advertising, continued high level of investment in R&D

Revenue Split

MCS

OPT

77.2%

of total revenue

• Growth of Ophthalmic Devices surpassed group revenue growth
• Higher recurring revenue weight makes business more resilient amid supply chain constraints and less cyclical against hospitals' investment

ZEISS

Page 5